eMedicine Specialties > Ophthalmology > Cornea

Herpes Simplex

Robert H Graham, MD, Senior Associate Consultant, Department of Ophthalmology, Mayo Clinic, Scottsdale, Arizona
Kerry Assil, MD, Medical Director and CEO, The Sinskey Eye Institute
Contributor Information and Disclosures

Updated: Jun 18, 2006

Introduction

Background

Herpes simplex virus (HSV), a large complex DNA virus, commonly infects the skin and the mucous membranes in the regions of the mouth, genitalia, and eye. Two antigenically related strains of HSV can be distinguished, type 1 and type 2. Type 1 most commonly is associated with infections of the orofacial area and the ocular surface, while type 2 causes genital disease.

Pathophysiology

Infection is spread by direct contact of skin or mucous membranes to infected secretions. The initial attack generally is self-limited and often is subclinical. However, herpetic disease is recurrent, and a wide range of clinical manifestations can result from an infection with this agent. The most common site of primary infection in humans is the skin and the mucous membrane innervated by the trigeminal nerve. The virus is transported via the nerve axon to its cell body in the sensory ganglion where it persists in a latent state until reactivation. Some indication exists that the human cornea also may harbor latent virus. Recurrent disease is the result of reactivation of this latent virus.

Frequency

United States

Of adults in the US, 50-90% have antibodies to HSV type 1, indicating previous exposure to the virus. Incidence of ocular HSV infection is approximately 0.15%.

Mortality/Morbidity

HSV keratitis is the most frequent cause of corneal blindness in the US, with reports of any visual disability as high as 40%.

Sex

This condition has a slightly higher male predominance.

Age

The mean age of presentation is in the late fifth to early sixth decade of life.

Clinical

History

  • Patients may present with the following:
    • Red eye
    • Pain
    • Photophobia
    • Tearing
    • Decreased vision
    • Skin (eg, eyelid) rash
  • History of previous episodes
  • History of corneal abrasion; contact lens wear; or previous nasal, oral, or genital sores

Physical

Primary herpes infection of the eye typically is a unilateral blepharoconjunctivitis, characterized by vesicles on the skin of the lids, follicular conjunctivitis, preauricular adenopathy, and, sometimes, punctate keratitis. After primary infection, recurrent disease may involve any or all layers of the cornea. Since both infectious and immune responses are responsible for ocular disease, it is better to classify the keratitis based upon both the anatomical location (ie, epithelial, stromal, endothelial) and on the pathophysiology (ie, infectious, immune, neurotrophic). Based on this mechanism of classification, 4 major categories of herpes simplex keratitis exist.

  • Infectious epithelial keratitis
    • Corneal vesicles: These are minute, raised, clear vesicles in the corneal epithelium that correspond to the vesicles on the skin surface. Within a few hours, these vesicles coalesce and erupt to form a dendritic or geographic ulcer. In immunocompromised individuals, they may coalesce without eruption, forming a raised dendrite without ulceration that shows reverse staining with fluorescein.
    • Dendritic ulcer: This is the most common presentation. The lesion reveals a linear branching pattern with terminal bulbs and heaped borders that contain live virus.
    • Geographic ulcer: As the dendritic ulcer widens, it looses its linear pattern and assumes a geographic form, with scalloped edges and heaped borders. This tends to occur in patients immunocompromised by the use of topical steroids or diseases (eg, HIV).
    • Marginal ulcer: When a dendrite develops close to the limbus its anterior stroma gets infiltrated by leukocytes from the limbal blood vessels, resulting in a dendritic lesion overlying an anterior stromal infiltrate. This often can be mistaken for a marginal staphylococcal ulcer.
  • Neurotrophic keratopathy: This is neither infectious nor immune in nature, but the result of abnormal corneal innervation and poor tear production. A nonhealing, oval epithelial defect develops. This defect has smooth borders in contrast to geographic ulcers, which have scalloped borders. Over time, stromal ulceration and opacification develop under the epithelial defect. Corneal perforation can occur.
  • Stromal keratitis develops in 25% of patients with epithelial disease.
    • Necrotizing stromal keratitis presents as necrosis and dense infiltration of the stroma, with an overlying epithelial defect. This is a result of direct stromal invasion by the virus. This entity may resemble bacterial or fungal keratitis. The use of topical corticosteroids without antiviral coverage is a risk factor in developing necrotizing keratitis.
    • Nonnecrotizing stromal keratitis also is called immune stromal keratitis and interstitial keratitis. An antigen antibody inflammatory response is believed to be triggered by retained viral antigens in the corneal stroma. Stromal infiltration with or without neovascularization occurs. The overlying epithelium is intact, unless a concomitant infectious or neurotrophic keratitis is present.
  • Endotheliitis is an immune reaction at the level of the endothelium that may occur months to years after an episode of infectious keratitis. Characteristic findings include keratic precipitates (KP), overlying stromal and possibly epithelial edema, and iritis. Unlike stromal edema from primary stromal keratitis, no stromal infiltrates or neovascularization is present. Patients present with pain, photophobia, and injection. Based on the distribution of the KP, 3 recognized forms of endotheliitis can be identified.
    • Disciform endotheliitis presents as a round area of central or paracentral stromal edema overlying an area of KP.
    • Diffuse endotheliitis presents with scattered KP and diffuse edema.
    • Linear endotheliitis: Keratic precipitates develop in the peripheral cornea and proceed centrally. Associated corneal edema is isolated to the peripheral corneal stroma and epithelium.

Causes

Primary herpes keratitis is a ubiquitous disease with no apparent risk factors. Recurrent infection due to reactivation, and occasionally reinfection, can be triggered by many events, including the following:

  • Stress
  • Sunlight
  • Fever
  • Menstruation
  • Trauma including surgical trauma (eg, lamellar keratoplasty, peripheral iridectomy)
  • Antiglaucoma medication latanoprost, a prostaglandin analogue because of its ability to induce release of endogenous prostaglandins in the iris and ciliary muscles can induce reactivation of HSV keratitis

Contents

Overview: Herpes Simplex
Differential Diagnoses & Workup: Herpes Simplex
Treatment & Medication: Herpes Simplex
Follow-up: Herpes Simplex

References

  1. Carr DJ, Tomanek L. Herpes simplex virus and the chemokines that mediate the inflammation. Curr Top Microbiol Immunol. 2006;303:47-65. [Medline].

  2. Cobo LM, Coster DJ, Rice NS. Prognosis and management of corneal transplantation for herpetic keratitis. Arch Ophthalmol. Oct 1980;98(10):1755-9. [Medline].

  3. Herpetic Eye Disease Study Group. A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis. The Epithelial Keratitis Trial. Arch Ophthalmol. Jun 1997;115(6):703-12. [Medline].

  4. Herpetic Eye Disease Study Group. A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. Arch Ophthalmol. Sep 1996;114(9):1065-72. [Medline].

  5. Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med. Jul 30 1998;339(5):300-6. [Medline].

  6. Holland EJ, Schwartz GS. Classification of herpes simplex virus keratitis. Cornea. Mar 1999;18(2):144-54. [Medline].

  7. Kabra A, Lalitha P, Mahadevan K. Herpes simplex keratitis and visual impairment: a case series. Indian J Ophthalmol. Mar 2006;54(1):23-7. [Medline].

  8. Kaiserman I, Kaiserman N, Nakar S. Herpetic eye disease in diabetic patients. Ophthalmology. Dec 2005;112(12):2184-8. [Medline].

  9. Kaufman HE, Martola EL, Dohlman CH. Herpes simplex treatment with IDU and corticosteroids. Arch Ophthalmol. 1963;69:468-72.

  10. Koelle DM, Ghiasi H. Prospects for developing an effective vaccine against ocular herpes simplex virus infection. Curr Eye Res. Nov 2005;30(11):929-42. [Medline].

  11. Kothari MT, Mehta BK, Asher NS. Recurrence of bilateral herpes simplex virus keratitis following bimatoprost use. Indian J Ophthalmol. Mar 2006;54(1):47-8. [Medline].

  12. Levy J, Lapid-Gortzak R, Klemperer I. Herpes simplex virus keratitis after laser in situ keratomileusis. J Refract Surg. Jul-Aug 2005;21(4):400-2. [Medline].

  13. Li H, Zhang J, Kumar A. Herpes simplex virus 1 infection induces the expression of proinflammatory cytokines, interferons and TLR7 in human corneal epithelial cells. Immunology. Feb 2006;117(2):167-76. [Medline].

  14. Liesegang TJ, Melton LJ 3d, Daly PJ, et al. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. Aug 1989;107(8):1155-9. [Medline].

  15. Lu CK, Chen KH, Lee SM. Herpes simplex keratitis following excimer laser application. J Refract Surg. May 2006;22(5):509-11. [Medline].

  16. Pepose JS, Keadle TL, Morrison LA. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy. Am J Ophthalmol. Mar 2006;141(3):547-557. [Medline].

  17. Rao SN. Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol. Apr 2006;141(4):771-2. [Medline].

  18. Saini JS, Agarwala R. Clinical pattern of recurrent herpes simplex keratitis. Indian J Ophthalmol. Mar 1999;47(1):11-4. [Medline].

  19. Seitzman GD, Cevallos V, Margolis TP. Rose bengal and lissamine green inhibit detection of herpes simplex virus by PCR. Am J Ophthalmol. Apr 2006;141(4):756-8. [Medline].

  20. Sozen E, Avunduk AM, Akyol N. Comparison of efficacy of oral valacyclovir and topical acyclovir in the treatment of herpes simplex keratitis: a randomized clinical trial. Chemotherapy. 2006;52(1):29-31. [Medline].

  21. Tabbara KF. Treatment of herpetic keratitis. Ophthalmology. Sep 2005;112(9):1640. [Medline].

  22. Wilhelmus KR, Gee L, Hauck WW, et al. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. Dec 1994;101(12):1883-95; discussion 1895-6. [Medline].

  23. Wilhelmus KR. Diagnosis and management of herpes simplex stromal keratitis. Cornea. 1987;6(4):286-91. [Medline].

  24. Zaher SS, Sandinha T, Roberts F. Herpes simplex keratitis misdiagnosed as rheumatoid arthritis-related peripheral ulcerative keratitis. Cornea. Nov 2005;24(8):1015-7. [Medline].

  25. de Rojas Silva MV, Diez-Feijoo E, Javaloy J. Prophylactic perioperative antiviral therapy for LASIK in patients with inactive herpetic keratitis. J Refract Surg. Apr 2006;22(4):404-6. [Medline].

Further Reading

Keywords

HSV, keratitis, corneal ulcer, dendrite, conjunctivitis

Contributor Information and Disclosures

Author

Robert H Graham, MD, Senior Associate Consultant, Department of Ophthalmology, Mayo Clinic, Scottsdale, Arizona
Robert H Graham, MD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, and Arizona Ophthalmological Society
Disclosure: Nothing to disclose

Coauthor

Kerry Assil, MD, Medical Director and CEO, The Sinskey Eye Institute
Kerry Assil, MD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, Association for Research in Vision and Ophthalmology, and Contact Lens Association of Ophthalmologists
Disclosure: Nothing to disclose

Medical Editor

Kilbourn Gordon III, MD, FACEP, Urgent Care Physician, Primary Medical, Huntington Walk-In and Greenwich Convenient Medical Center
Kilbourn Gordon III, MD, FACEP is a member of the following medical societies: American Academy of Ophthalmology, American College of Emergency Physicians, and Wilderness Medical Society
Disclosure: Nothing to disclose

Pharmacy Editor

Simon K Law, MD, PharmD, Assistant Professor of Ophthalmology, Jules Stein Eye Institute; Chief of Section of Ophthalmology Surgical Services, Department of Veterans Affairs Healthcare Center, West Los Angeles
Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose

Managing Editor

Christopher J Rapuano, MD, Professor, Department of Ophthalmology, Jefferson Medical College; Co-Chairman of the Cornea Service, Co-Chairman of Refractive Surgery Department, Wills Eye Hospital
Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Eye Bank Association of America, Pennsylvania Medical Society, and Philadelphia County Medical Society
Disclosure: Allergan Honoraria for Speaking and teaching; Allergan Consulting fee for Consulting; Alcon Honoraria for Speaking and teaching; Inspire Honoraria for Speaking and teaching; RPS Ownership interest for Other

CME Editor

Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose

Chief Editor

Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.